atv-1601
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 29, 2025 (NCT07038369)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Diseases · Phase 1
- Breast Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Genital Neoplasms, Female · Phase 1
- Neoplasms · Phase 1
- Neoplasms by Site · Phase 1
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urogenital Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
- Uterine Neoplasms · Phase 1
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
AKT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07038369 | Phase 1 | Jul 29, 2025 | Atavistik Bio, Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atavistik Bio, Inc | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1